Victoza (liraglutide) tracker
Educational reference for Victoza (liraglutide). Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
13 h
Tmax
11 h
Category
glp1
> PLACEHOLDER — pending clinical review by licensed pharmacist. Victoza is an FDA-approved liraglutide brand for type 2 diabetes. Subcutaneous injection.
Mechanism
Victoza is a brand name for liraglutide, a GLP-1 receptor agonist. See the liraglutide entry for the full mechanism.
Research summary
Victoza is the once-daily liraglutide product approved for type 2 diabetes (LEAD program; cardiovascular outcomes in LEADER). For weight management, the liraglutide product Saxenda is used. See the liraglutide entry.
Dosing in the literature
Regimens are individualized and set by a prescribing clinician; they are outside the scope of this summary. See the liraglutide entry.
Reported side effects
As a liraglutide product, gastrointestinal effects are most commonly reported; prescribing information includes class warnings. See the liraglutide entry. This is not a complete safety profile.
Stacking notes
See the liraglutide entry. Combination with insulin or sulfonylureas raises hypoglycemia considerations.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Victoza prescribing information · FDA prescribing information (2010)available via DailyMed; see liraglutide entry
Track Victoza (liraglutide) in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.